Cue Biopharma, Inc. (CUE)

PHARMACEUTICAL PREPARATIONS

Cue Biopharma, Inc. (CUE) is listed on Nasdaq, where it has traded since January 2, 2018.

Listed On
Nasdaq
Listed Since
January 2, 2018
Employees
29
Market Cap
$228M

About Cue Biopharma, Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 47 institutions reported holding CUE, with 1.6 million shares worth $51.8 million in aggregate. The largest reported holder was Bleichroeder, with 370,682 shares worth $11.7 million. Of the 5 largest holders listed below, 3 opened new positions in CUE and 2 added shares during the quarter.

InstitutionSharesValueQuarter change
Bleichroeder370,682$12MAdded 63.08%
Driehaus Capital Management292,144$9MNew position
Vanguard187,813$6MAdded 86.94%
Ikarian Capital104,364$3MNew position
Tfg Asset Management GP93,819$3MNew position

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is CUE?

Cue Biopharma, Inc. (CUE) is listed on Nasdaq, where it has traded since January 2, 2018.

Who are the largest institutional holders of CUE?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of CUE were Bleichroeder, Driehaus Capital Management and Vanguard.

How many institutions own CUE?

47 institutions reported a position in CUE for the quarter ended June 30, 2026, worth $51.8 million in total.

Did institutions buy or sell CUE last quarter?

Of the 5 largest reported holders, 3 opened new positions in CUE and 2 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for CUE.

Every reported institutional holder, plus insider and congressional trades in CUE, on SentiSense.